GSK reports £8.89 billion in third quarter 2026 earnings

GSK reported £8.89B in Q3 2026 earnings, exceeding estimates due to specialty medicine sales growth. Revenue rose 5% at constant exchange rates, while operating profit fell 16% to £2.13B. The company expects 3-5% full-year turnover growth and maintained its 17p quarterly dividend.

Original reporting
Published Oct 28, 2026, 9:08 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 28, 2026, 10:07 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
GSK reports £8.89 billion in third quarter 2026 earnings — source image
Decision brief

The 30-second read

$GSKBullishHigh
01

Why it matters

The earnings beat may trigger buying interest, but investors should monitor profit margin trends and currency effects.

02

Market read

First‑report earnings with material numbers for a large‑cap pharma firm, likely influencing sector sentiment.

03

What to watch

Potential currency headwinds and vaccine portfolio weakness may limit upside.

Relevance 8/10Novelty 9/10Timing: pre‑market today

Background

GSK's third‑quarter earnings were released on 28 Oct 2026, providing the latest financial performance and guidance.

Company-level read

Ticker impact

$GSKBullishHigh confidence
Context

GSK reported Q3 revenue of £8.89 bn, beating expectations and provided full‑year turnover guidance of 3‑5% growth.

Expected impact

likely upward pressure as the market prices in the revenue beat and growth guidance

Evidence & confidence

Revenue exceeded consensus, operating profit decline was limited, and guidance is higher than prior expectations, which typically supports a price rise.

Market effects

strengthens the healthcare/pharma sector outlook, especially specialty medicines

supports UK and European pharma stocks after the release

adds to global earnings momentum in the biotech/pharma space

Counterpoint

The operating profit decline and restructuring charge could weigh on margins, suggesting caution despite the revenue beat.

Key entities

  • GSK

    Global healthcare and pharmaceutical company

Related articles

$LLYMedAI 8/10

Rx Rundown: Ollin Biosciences, AstraZeneca, Isomorphic Labs and more

Eli Lilly, AbbVie, Johnson & Johnson, and others announced major deals and acquisitions in the biopharma sector, totaling billions. AstraZeneca, Roche, and Novo Nordisk received FDA approvals for new treatments. Isomorphic Labs raised $5 billion in private financing. AstraZeneca cut 600 jobs, while Cellectis plans to cut 70% of its workforce.

$GSKMed

Nelkarmi gives ALK-positive lung cancer patients a new option after first-line therapy stops working

GSK's Nelkarmi (neladalkib) received FDA accelerated approval for ALK-positive NSCLC patients after prior ALK therapy. Approval based on ALKOVE-1 trial showing 49% tumor shrinkage in Alecensa-only group. GSK acquired Nelkarmi via Nuvalent acquisition. Continued approval contingent on confirmatory trial. ALKAZAR phase 3 trial ongoing for first-line treatment.

$GSKMedAI 8/10

GSK’s $10.6bn Nuvalent bet pays off with second lung cancer drug approval

GSK's Nelkarmi (neladalkib) received FDA approval for treating ALK-positive non-small cell lung cancer, the second drug from its $10.6bn Nuvalent acquisition. The approval was based on trial results showing a 49% response rate. GSK expects significant sales, with forecasts predicting $1.2bn by 2032. Roche's Alecensa is a key competitor. Approval hinges on ongoing Phase III trial results.

$GSKMed

GSK Wins Second Lung Cancer Approval of 2026 as FDA Clears Nelkarmi — BigGo Finance

GSK (GSK) received FDA approval for Nelkarmi, a lung cancer drug, based on Phase 1/2 trial data. The drug targets ALK gene mutations and showed activity against brain metastases. GSK acquired Nelkarmi through its $10.6B Nuvalent deal. Analysts project $1B in 2032 sales, with peak sales estimates of $5B-$7B for GSK's lead Nuvalent drugs. The approval is seen as a validation of GSK's oncology portfolio strategy.